A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
Latest Information Update: 30 Aug 2017
Price :
$35 *
At a glance
- Drugs Pemetrexed (Primary)
- Indications Adenocarcinoma; Cervical cancer
- Focus Therapeutic Use
- 22 Aug 2017 Status changed from recruiting to discontinued.
- 19 Aug 2016 New trial record